The Role of Syk/CARD9-Coupled C-Type Lectin Receptors in Immunity to Mycobacterium tuberculosis Infections by Marakalala, Mohlopheni Jackson et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2010, Article ID 567571, 9 pages
doi:10.1155/2010/567571
Review Article
TheRoleofSyk/CARD9-CoupledC-TypeLectinReceptorsin
Immunity to Mycobacteriumtuberculosis Infections
Mohlopheni Jackson Marakalala,1 LisaM.Graham,1 and Gordon D. Brown2
1Institute of Infectious Diseases and Molecular Medicine, Division of Immunology, CLS, University of Cape Town,
Cape Town 7925, South Africa
2Aberdeen Fungal Group, Section of Immunology and Infection, Division of Applied Medicine, Institute of Medical Sciences,
University of Aberdeen, Aberdeen AB25 2ZD, UK
Correspondence should be addressed to Gordon D. Brown, gordon.brown@abdn.ac.uk
Received 1 November 2010; Accepted 16 December 2010
Academic Editor: Taro Kawai
Copyright © 2010 Mohlopheni Jackson Marakalala et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
There is increasing interest in understanding the mechanisms underlying the interactions that occur between Mycobacterium
tuberculosis and host innate immune cells. These cells express pattern recognition receptors (PRRs) which recognise mycobacterial
pathogen-associated molecular patterns (PAMPs) and which can inﬂuence the host immune response to the infection. Although
many of the PRRs appear to be redundant in the control of M. tuberculosis infection in vivo, recent discoveries have revealed a key,
nonredundant, role of the Syk/CARD9 signalling pathway in antimycobacterial immunity. Here we review these discoveries, as
well as recent data investigating the role of the Syk/CARD9-coupled PRRs that have been implicated in mycobacterial recognition,
including Dectin-1 and Mincle.
1.Introduction
Despiteoveracenturyofresearch,tuberculosis(TB)remains
the deadliest bacterial infection causing about 1.6 million
deaths per year worldwide [1]. In most cases of TB
infection, the immune response is successful in containing
Mycobacterium tuberculosis (MTB), which then remains in a
dormant, nonreplicative state, termed latency. This clinical
latency often extends for the lifetime of the individual but
reactivation of the infection can occur due to perturbations
of the immune system [2]. An estimated one-third of the
world’s population are latently infected with MTB, and
about 10% of these people are likely to become sick with
active TB in their lifetime. The emergence of new resistant
strains as well as coinfection with HIV also provides more
challenges in the treatment of TB, making it a global
problem that needs urgent attention [1]. Thus development
of new antitubercular drugs and a more eﬀective vaccine is
a priority; both of which depend, in large part, on obtaining
a better understanding of interaction between the host and
this pathogen.
The immune system of humans and other mammals
is comprised of two interrelated components, the innate
and adaptive response, both of which are required for the
resolution of the infection. The innate immune system, in
particular, consists of phagocytes such as macrophages and
dendritic cells which are involved in the initial capture of the
bacteria, as well as the presentation of microbial antigens.
Serving as ﬁrst line of defence, these innate cells express
a variety of evolutionarily conserved pattern recognition
receptors (PRRs), which are involved in the recognition of
pathogen-associated molecular patterns (PAMPs) [3].
One of the ﬁrst events after the inhaled mycobacteria
have reached the alveolar space is its recognition by alveolar
macrophage PRRs. The role of PRRs, such as the toll-
like receptors (TLRs) and NOD-like receptors (NLRs), in
antimycobacterialimmunityhasbeenafocusofconsiderable
interest [4, 5]. TLR-2, TLR-4, for example, were shown to
play a role in the long-term control of M. tuberculosis [4].
Furthermore, TLR-9 was reported to be important in the
induction of protective responses, and in cooperation with
TLR-2, to mediate resistance to MTB infection [6]. Studies2 Clinical and Developmental Immunology
using MyD88-deﬁcient mice also demonstrated a role of this
downstream adaptor in the acute control of MTB infection
[7]. However, recent data have shown that MyD88 and
TLR-2, -4, and -9 are dispensable for the induction of T
cell-mediated adaptive immunity to MTB infection [8, 9].
TLR-2, -4, and -9-deﬁcient mice were also not impaired in
theirmacrophageeﬀectormechanismsanddisplayednormal
control of MTB replication [8]. Thus, the TLRs, even in
combination, appear to be redundant for the control of MTB
infection.
Nucleotide-binding oligomerization domain proteins
(NODs) are modular cytoplasmic proteins that recognise
components of peptidoglycan [4]. NOD2 is the widest
studied NLR in the MTB infections and has been shown to
synergizewithTLR-2fortheproductionofproinﬂammatory
cytokines in response to MTB. Gandotra et al. have reported
that NOD2-deﬁcient macrophages and DCs were impaired
in the production of proinﬂammatory cytokines in response
to live MTB. However this NLR seems to be dispensable
in the in vivo control of the infection, as NOD2-deﬁcient
and the wild-type control mice show similar levels of
susceptibility when infected with virulent MTB [10]. More
work is needed to understand the role of other NLRs in
antimycobacterial infections.
Other PRRs have also been implicated in the immune
response to M. tuberculosis, including the mannose receptor
(MR), complement receptor 3 (CR3), dendritic cell-speciﬁc
intercellular adhesion molecule 3 (ICAM-3)-grabbing non-
integrin (DC-SIGN), class A scavenger receptor, mannose
binding lectin (MBL), and surfactant protein A (Sp-A) [11,
12]. Nonetheless, each of these receptors also seem to be
functionally redundant, as it has been shown that single
deﬁciencies in PRRs such as Scavenger receptor A, CD36,
MARCO, mannose receptor, and SIGNR1 do not impair the
control of M. tuberculosis in vivo [13]. Thus, we and others
have speculated that mycobacteria are likely to simultane-
ously engage multiple receptors and that deﬁciency of one
receptor can be compensated by another [5, 13]. However,
recent discoveries suggestthat the Syk/CARD9 pathway plays
a nonredundant role in antimycobacterial immunity, and
twoC-typelectinreceptors(CLRs)recognisingmycobacteria
that utilise this pathway have been identiﬁed. Here we review
our current understanding of the Syk/CARD9 pathway, as
well as the two CLRs (macrophage-inducible C-type lectin
(Mincle) and Dectin-1), with particular emphasis on their
roles in antimycobacterial immunity.
2.CARD9 (CaspaseRecruitment
Domain-ContainingProtein9): AnAdaptor
Molecule InvolvedinITAM-Coupled
Receptor Signalling
CARD9isanadaptormoleculethatcontainsN-terminalcas-
pase recruitment domain (CARD) and a C-terminal coiled-
coil region that is important for protein oligomerization
[14]. Structurally, this adaptor is related to CARMA (CARD
MAGUK) family of proteins, which include CARMA1
(CARD11), CARMA2 (CARD10), and CARMA3 (CARD13)
[15]. Originally discovered through a database search of
CARD-containing proteins, CARD9 is expressed in various
tissues including the lung, liver, spleen, placenta, peripheral
bloodleukocytes,andbonemarrow.CARD9isnotexpressed
in lymph nodes, T cells, or B cells, but is abundantly
expressed in innate myeloid cells including dendritic cells
and macrophages [14, 16].
This adaptor protein operates downstream of immun-
oreceptor tyrosine-based activation motif-(ITAM-) associ-
ated PRRs and cooperates with B cell lymphoma 10 (Bcl10)
and the paracaspase MALT1 to form a trimolecular complex
that transduces signalling to the canonical NFκBp a t h w a y
[15]. CARD9 was initially identiﬁed as a key transducer of
Dectin-1 signalling [17], but more recently this signalling
pathway has also been shown to be important for myeloid
cell activation via DAP12- and FcRγ-associated receptors
[18].
Several murine studies have demonstrated that CARD9
plays an essential role in protection against fungal and
bacterial pathogens, including C. albicans and Listeria mono-
cytogenes [16, 17]. A recent study by Glocker et al. has
described a CARD9 mutation in humans that is associated
with an increased susceptibility to chronic mucocutaneous
candidiasis [19]. Interestingly, these patients had signiﬁ-
cantly reduced numbers of Th17 cells [19], and murine
studies have shown that signalling through the CARD9
pathway, from receptors including Dectin-1 (see below)
and Dectin-2, is important for the development of these
types of adaptive responses [20–22]. Indeed, LeibundGut-
Landmann et al. have shown that CARD9 is indispensable
for the induction of Th17 responses in mice infected with
C. albicans [20]. Poeck et al. have recently shown that RIG-I
engagesCARD9-Bcl10signallingpathwayfortheproduction
of IL-1β in response to RNA viruses [23]. Thus CARD9 is a
central molecule that transduces signals from multiple PRRs
to induce immunity to various pathogens.
3. CARD9 andAntimycobacterialImmunity
The essential role of CARD9 control of pulmonary tuber-
culosis, at least in mice, was recently demonstrated by
Dorhoi et al. [24]. These authors found that Card9−/−
mice succumbed rapidly to aerosol infection with M.
tuberculosis H37Rv, and, compared with their littermate
controls, the CARD9-deﬁcient mice had signiﬁcantly higher
pulmonary bacillary burdens and more profound tissue
damage, characterized by acute pneumonia with accelerated
accumulation of inﬂammatory cells. There was also evidence
of secondary necrosis in the Card9−/− lung tissue, suggesting
a correlation between cell death in lungs of these mice and
their susceptibility to tuberculosis infection [24].
To investigate the eﬀect of CARD9 deﬁciency in the
activation of antigen presenting cells (APCs), Dorhoi et al.
infected bone-marrow-derived macrophages (BMMø) with
MTB H37Rv and analyzed various innate responses. Both
the WT and Card9−/− BMMø produced similar levels of
nitric oxide (NO), and the adaptor deﬁciency did not have
an eﬀect on internalization or killing of MTB after IFN-γClinical and Developmental Immunology 3
activation. The authors also demonstrated that the clearance
of apoptotic cells was also not impaired in Card9−/− BMMø.
Furthermore, apoptotic cell death occurred at similar fre-
quency in both the WT and Card9−/− cells [24]. However,
infected Card9−/− BMMø had signiﬁcant reductions in the
synthesis of proinﬂammatory cytokines, TNF, IL-1β,a n dI L -
6, and produced less IL-12 and CCL5, when compared to
the WT cells. The MTB-infected Card9−/− BMDCs were also
impaired in their ability to synthesise TNF and IL-1β. These
data indicated that CARD9 is critical for activation of innate
immune cells following the recognition of MTB [24].
To characterize the PRRs involved in APC activation,
Dorhoi et al. stimulated BMMø and DCs with MTB-derived
PAMPs, including manLam, peptidoglycan (PG), mycolyl-
arabinogalactan peptidoglycan (mAGP), and mycobacterial
cord factor. The stimulation with manLam and cord factor
led to cellular activation, suggesting possible involvement
of MR and Mincle [24, 25] (see below). The stimulation
of wild-type BMMø and DCs with mAGP triggered the
r e l e a s eo fT N Fa n dI L - 1 0 ,w h i c hw e r ea b r o g a t e di nt h e
CARD9-deﬁcient cells. These results suggested the involve-
ment of nucleotide-binding oligomerization domain protein
2 (NOD2) in the CARD9-mediated innate response to
MTB [24], as mAGP-induced cytokine production has been
previously shown to partially depend on this receptor [10].
Furthermore, the authors showed that the treatment of
wild-type BMMø with laminarin (a β-glucan antagonist
of Dectin-1) and piceatannol (a Syk kinase inhibitor)
speciﬁcally blocked TNF and IL-6 production, suggesting
that signalling through the Dectin-1/Syk pathway was also
important in the induction of MTB-triggered proinﬂam-
matory responses [24]. Thus, the authors speculated that
during MTB recognition CARD9 is likely to converge signals
from a number of PRRs to mediate innate responses to this
pathogen [24].
To characterize the role of CARD9 in adaptive cell
responses, Dorhoi et al. measured various T cell populations
and the recruitment of leukocytes to the lungs following
infection with MTB. At day 14 postinfection, there were
no diﬀerences between WT and Card9−/− mice in the
recruitment of T cell subpopulations to the lung. Also,
the ratio of CD4+/CD8+ cells in the wild-type and the
knockout mice were similar at both days 14 and 28 after
infection. Furthermore, there were similar frequencies of
CD8+ T cells and FoxP3+ T lymphocytes in both groups
of mice [24]. Thus, CARD9 deﬁciency does not aﬀect T
cell responses in MTB infection. In addition to T cells, the
authors showed that there was no diﬀerence in the frequency
of lung macrophages, DCs, as well as the expression of CD86
(an APC-expressed maturation marker) [24].
There was, however, a substantial accumulation of neu-
trophils in the lungs of CARD9-deﬁcient mice compared
to the wild-type control mice. The accelerated recruitment
of the polymorphonuclear neutrophils (PMNs) to the lung
corresponded to the disease progression, implicating these
cells in the susceptibility of Card9−/− mice to MTB infec-
tion [24]. In an endeavour to determine what triggered
the neutrophilic inﬂammation during the infection, the
authors measured chemokine and cytokine levels in serum
and lung homogenates. Intriguingly, MCP-1, KC, and G-
CSF were signiﬁcantly higher in the Card9−/− mice. In
addition, elevated concentrations of granulocyte-derived
myeloperoxidase (MPO) were detected in sera of these
mice compared to the wild type control animals. Thus, the
authors conclude that the systemic inﬂammatory disease
that leads to tissue damage emanates from G-CSF-mediated
augmented granulocyte diﬀerentiation and the KC-driven
accelerated recruitment of the neutrophils to the lung [24].
Rescue experiments performed by either neutralizing G-
CSF or depleting PMN with anti-Gr-1 monoclonal antibody
resulted in the reduction of lung inﬂammation and pro-
longedsurvival.Furthermore,theauthorsalsodemonstrated
that the CARD9-deﬁcient PMNs lost their capacity to
produce IL-10 upon MTB challenge and thus failed to ﬁne-
tune the level of inﬂammation in the lung [24]. Collectively,
the data by Dorhoi et al. demonstrates an essential role of
CARD9 signalling in the control of MTB infection [24].
In another recent study, Werninghaus et al. reported
that the mycobacterial PAMP, trehalose-6,6-dimycolate
(TDM, cord factor), and its synthetic analogue trehalose-
6,6-dibehenate (TDB) activate antigen presenting cells,
macrophages, and DCs, via the Syk-CARD9 pathway to
induce innate responses such as NO production and the
release of cytokines such as TNF, IL-1β, and IL-6 [25]. TDM
was ﬁrst identiﬁed in 1950 by Bloch as a glycolipid that
was responsible for cording in tubercle bacilli [26], and
six decades later this glycolipid remains one of the widely
studied components of mycobacterial cell membrane mainly
due to its ability to activate the innate immune system in
mammals [27]. Werninghaus et al. showed in vivo that these
glycolipidscouldbeusedasadjuvantstodrivecombinedTh1
and Th17 T cell responses to an MTB subunit vaccine in a
CARD9-dependent manner [25]. These responses were also
FcRγ-dependent and subsequently identiﬁed to be mediated
through Mincle (see below).
4.Dectin-1Structure,Expression,
andSignalling
Dectin-1 is a glycosylated type II transmembrane receptor
possessing a single extracellular C-type lectin-like domain
(CTLD) and a cytoplasmic signalling domain which is
involved in cellular activation [28, 29]. This receptor was
ﬁrst discovered through subtractive cDNA cloning from
murine dendritic cells (DCs) [30] and later identiﬁed and
characterizedinhumans[31,32].Inbothoftheseorganisms,
alternative splicing of Dectin-1 results in two major isoforms
and a number of minor isoforms, with the major ones
diﬀering in the presence or absence of the stalk region
[31, 33]. Dectin-1 is predominantly expressed on myeloid
cells, including dendritic cells, monocytes/macrophages, and
neutrophils, as well as a subset of T cells [34]. This PRR
has been shown to be expressed at high levels at portals
of pathogen entry, including the lung [34, 35]. Dectin-1
is a major β-glucan receptor on leukocytes [36]a n dc a n
mediate a variety of cellular responses including endocytosis,
phagocytosis, the respiratory burst, DC maturation, and the4 Clinical and Developmental Immunology
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Figure 1: Mincle- and Dectin-1-mediated signalling in response to mycobacteria. Upon recognition of their mycobacterial ligands, Dectin-1
and Mincle signal via the Syk/CARD9 pathway for the production of inﬂammatory cytokines and the induction of Th1 and Th17 responses.
There is also evidence that Dectin-1 signalling can cooperate with TLR2 to induce protective immunity.
induction of cytokine/chemokine production [28, 29]. Like
the TLRs, Dectin-1 can directly induce the development of
adaptive immunity, particularly Th17 and Th1 responses
[20, 37].
Increasing data from in vivo studies, although not
entirely consistent, have demonstrated an important role
for Dectin-1 in antifungal immunity [38, 39]. This receptor
has been shown to mediate recognition of several fungal
pathogens and to play an essential role in mouse models of
infection with Candida, Aspergillus, and Pneumocystis [40–
43]. In humans, deﬁciencies in Dectin-1 and in CARD9 have
recently been linked to susceptibility to fungal infections
[19, 44].
Dectin-1 signalling is mediated by the ITAM-like motif
also known as hemITAM. The ITAM motifs typically contain
an amino sequence comprising of a duplicate YxxL/I motif
(YxxL/Ix6−12YxxL/I), where Y is tyrosine, L is Leucine,
I is Isoleucine, and x denotes any amino acid [45, 46].
Upon ligand engagement, the ITAM-like motif of Dectin-1
becomes tyrosine phosphorylated by Src kinases, providing
a docking site for Syk kinase, which links the Dectin-
1 signalling to NF-κB activation via the CARD9-Bcl10-
MALT1 complex [17, 18]. In addition to the Syk-pathway
Dectin-1 can signal via a second pathway mediated by the
serine-threonine kinase Raf-1, which integrates with the Syk
pathway at the point of NF-κBa c t i v a t i o n[ 37]. Furthermore,
Dectin-1 can also trigger the activation of NFAT, which
regulates the induction of early growth response (Egr) family
transcription factors, Egr-2 and Egr-3 [47]. This activation
has been shown to occur through a pathway that requires
phospholipase C-γ2( P L C - γ2) [48]. Signalling from Dectin-
1 also interacts with pathways induced by other receptors,
such as the TLRs, resulting in the synergistic induction of
cytokines including TNF, IL-10, and IL-23 [49–51].
5.Dectin-1Recognition ofMycobacteria
Although the involvement of Dectin-1 in antifungal immu-
nity has been extensively characterized [29], the role of
this receptor in the control of mycobacterial infections
remains poorly understood. Studies from a number of
laboratories have implicated the role of Dectin-1 in response
to mycobacterial infections, although the ligand involved is
still unknown.
In the initial study, Yadav and Schorey demonstrated
that blocking Dectin-1 function with monoclonal antibodies
inhibited the production of TNF-α by bone-marrow-derived
murine macrophages (BMMø) infected with M. smegmatis
[52]. Cytokine production was also impaired in the TLR2-
deﬁcient macrophages, indicating the requirement of this
toll-like receptor for the Dectin-1-facilitated proinﬂamma-
tory responses. Dectin-1 was also shown to be required for
the production of RANTES, IL-6, and G-CSF in BMMø
infected with nonpathogenic strains such as attenuated M.
bovis and avirulent M. tuberculosis H37Ra (see Figure 1).Clinical and Developmental Immunology 5
Interestingly, Dectin-1 was not required for the induction
of macrophage proinﬂammatory responses upon infection
with virulent M.tuberculosisstrain, H37Rv [52]. The authors
argued that the minimal macrophage proinﬂammatory
response induced by the virulent mycobacterium might be
due to limited engagement of Dectin-1 by this strain [52].
However, in other studies (see below) Dectin-1 was found to
interact with virulent mycobacteria.
Rothfuchs et al. subsequently showed that Dectin-1
is important for IL-12p40 production in murine splenic
dendritic cells (SpDCs) infected with MTB [53]. The authors
demonstrated that blockade of Dectin-1 with laminarin
resulted in the reduction of IL-12p40 production by these
cells.Inaddition, theSpDCs fromDectin-1−/−chimeric mice
displayed reduced levels of IL-12p40 when compared to the
cells from the WT chimeras following stimulation with live
MTB or M. bovis. Furthermore, the production of IL-12p40
by the MTB-stimulated WT SpDCs was impaired by the
inhibition of Syk kinase with piceatannol [53]. However, in
these experiments TLR2 deﬁciency had no eﬀect. Rothfuchs
et al. further showed that a soluble Dectin-1-Fc fusion
protein [54] could bind to M. bovis BCG in a laminarin-
inhibitable manner [53].
Using the nontuberculous mycobacterium, M. abscessus,
Shin et al. demonstrated that the interaction of Dectin-1 and
TLR2 is required for the eﬃcient murine macrophage uptake
of this organism and subsequent Syk activation leading to
the production of TNF-α, IL-12p40, and IL-6 [55] (see
Figure 1). The observations on TLR2-Dectin-1 cooperation
are in agreement with the work by Yadav and Schorey [52],
but diﬀer with that of Rothfuchs et al. [53]; however, it
should be noted that each of these studies focussed on
diﬀerent cell types and mycobacterial species and/or strains.
Shinetal.alsodemonstratedtheimportanceofDectin-1/Syk
pathway in the production of ROS by BMMø infected with
M. abscessus [55].
More recently, the role of Dectin-1 in MTB-induced
innate immune responses has been examined in human
cells. Lee et al. have shown that the expression of Dectin-
1 mRNA and protein in A549 airway epithelial cells was
MTB-inducibleinaTLR2-dependentmanner.Theseauthors
also demonstrated the role of Dectin-1 in the production of
ROS, proinﬂammatory cytokines, and antimicrobial activity
during the intracellular growth of MTB in these cells [56].
In another study, Van de Veerdonk et al. showed that
Dectin-1 and TLR4 are the key receptors for the induction of
M.tuberculosis-triggeredIL-17AresponsesinhumanPBMCs
[57]. Furthermore, these authors demonstrated that the
blockade of IL-1β signalling with IL-1RA resulted in the
signiﬁcant decrease of IL-17A production by the PBMCs
infected with MTB. van de Veerdonk et al. concluded that
the endogenous IL-1 pathway plays a central role in the
induction of the MTB-induced Th17 response in human
PBMCs [57].
Using human monocyte-derived DCs, Zenaro et al. have
shown that stimulation of these cells with MTB leads to
the Dectin-1-dependent production of TNF-α,I L - 6 ,I L - 1 β,
and IL-23, enabling DCs to “instruct” CD4+ lymphocytes to
produce IL-17 and IFN-γ. The authors further investigated
the eﬀect of other receptors on these Dectin-1-dependent
responses and demonstrated that stimulation of the DCs
with biglycan and ManLAM (ligands of DC-SIGN and MR,
resp.) increased MTB-triggered T-cell production of IFN-γ
but resulted in the reduced amounts of IL-17. The authors
concluded that Dectin-1 interaction with MTB-stimulated
DCs induces Th1 and Th17 responses and that the DC-SIGN
andMR engagementwith DCs blocks the Dectin-1-triggered
mechanisms, therefore inhibiting Th17 and favouring Th1
responses [58].
To explore the role of this receptor in response to M.
tuberculosis in vivo, we characterized the eﬀect of Dectin-
1-deﬁciency in mice following aerosol infection with M.
tuberculosis H37Rv (MJM and GDB, paper in press). We
found a signiﬁcant and reproducible reduction (∼0.5log)
in the pulmonary bacilli burdens in the Dectin-1-deﬁcient
mice compared to the wild-type animals, but this did not
correlatewithanychangesinpulmonarypathology,cytokine
production, and ability to resist infection. Thus these data
suggest that Dectin-1 plays a minor role in antimycobacterial
immunity in vivo, at least in murine models.
More work is still required to understand the exact
role of this receptor in antimycobacterial immunity, and
in particular, the mycobacterial ligand(s) recognised by this
receptor.Mycobacteriadonotpossessβ-glucans,soitislikely
that Dectin-1 recognises a novel ligand on these pathogens.
The role of Dectin-1 in human mycobacterial infections also
warrants further investigation.
6. Mincle: An ITAM-Coupled FcRγ-Dependent
Signalling Receptor
Mincle is a type II C-type lectin belonging to the “Dectin-
2 cluster” of receptors [59, 60]. Also known as Clec4e and
Clecsf9, Mincle was ﬁrst identiﬁed by Matsumoto et al. as a
protein whose expression was induced by lipopolysaccharide
(LPS) [61]. The gene expression of Mincle was also shown
to be induced in peritoneal macrophages by several proin-
ﬂammatory cytokines, including IFN-γ,T N F - α,a n dI L - 6
[61]. However, Mincle expression was demonstrated to be
severelyimpairedinresponsetothesestimuliintheNF-IL-6-
deﬁcient macrophages indicating that Mincle is a transcrip-
tional target for NF-IL-6 [61]. Like other receptors in the
Dectin-2 cluster, particularly Dectin-2 and DCAR, Mincle is
expressed predominantly on cells of myeloid lineage, includ-
ing dendritic cells and macrophages [59, 61]. This receptor
is also expressed on B cells as well as on microglia in the
brain [59, 62]. Structurally, Mincle contains a single extra-
cellular carbohydrate recognition domain, a transmembrane
domain, and a short cytoplasmic domain without a known
signallingmotif[61].However,typicaloftheDectin-2cluster
of receptors, Mincle possesses a positively charged residue
near the transmembrane region through which it associates
with the adaptor FcRγ to trigger intracellular signalling via
Syk/CARD9 pathway [63, 64]. A report by Yamasaki et al.
has demonstrated that cross-linking Mincle on the surface
of peritoneal macrophages resulted in the production of
proinﬂammatory cytokines which were abrogated in FcRγ-
deﬁcient cells as well as CARD9-deﬁcient cells [64].6 Clinical and Developmental Immunology
Mincle can act as a receptor for both endogenous and
exogenous ligands, having been shown to recognise PAMPs
from a number of fungal pathogens, including C. albicans,
Saccharomyces cerevisiae, and Malassezia species [65–67].
Speciﬁcally, Wells et al. reported that Mincle recognises C.
albicans and that although this receptor did not act as a
phagocytic receptor, it played a role in TNFα production
in RAW264.7 and BMMøs in response to this fungus.
Furthermore, they demonstrated that Mincle-deﬁcient mice
displayed a signiﬁcantly greater fungal burden in the kidneys
compared to wild-type mice during systemic candidiasis
[66]. Bugarcic et al. further demonstrated that recombinant
CRDs of both human and mouse Mincle could recognise C.
albicans [65].
In contrast, Yamasaki et al. reported that C. albicans
was not recognised by Mincle using a cell-based reporter
system, but rather that the receptor speciﬁcally recognised
Malassezia species (a pathogen associated with skin diseases
such as tinea versicolor, folliculitis, and atopic dermatitis)
[67].However,thestrainsofCandidascreenedwerediﬀerent
from those reported by Wells et al. [66], and Yamasaki
and coworkers have suggested that Mincle may distinguish
between diﬀerent strains of C. albicans [67]. Recognition of
Malassezia by Mincle was shown to require the mannose
binding EPN-motif in the receptor’s CRD, as well as Ca2+,
and α-mannose was identiﬁed as the ligand of this receptor
[67]. Stimulation of BMMø with Malassezia resulted in the
production of MIP-2, KC, IL-10, and TNF-α, which was
signiﬁcantly reduced in the Mincle-deﬁcient macrophages
[67]. Additionally, intraperitoneal injection of this fungus
resulted in impaired IL-6 and TNFα production and neu-
trophil inﬁltration in Mincle-deﬁcient mice compared to
wild-type mice [67]
In addition to the role in fungal recognition, Yamasaki
et al. have demonstrated that Mincle senses necrosis. Using
an NFAT-GFP-based reporter system the authors found that
GFP expression was greatly increased in the presence of
necrotic cells, as well as with supernatants from necrotic cells
and lysates generated from normal cells. Mutation of the
EPN motif in the CRD did not reduce recognition of the
deadcells,suggestingthatMinclerecognisedtheendogenous
ligand in a carbohydrate independent manner. The authors
subsequently identiﬁed spliceosome-associated protein 130
(SAP130),apreformedsolublefactorreleaseduponnecrosis,
as a ligand for this receptor. Stimulation of peritoneal
macrophages or Mincle expressing T cell hybridomas with
SAP130 resulted in MIP-2 and IL-2 production, respec-
tively. In vivo, the authors demonstrated that inﬂammatory
responses induced by this PRR promoted the inﬁltration of
neutrophils to the site of necrosis, induced either by whole
body irradiation or by peritoneal injection of necrotic cells
[64].
7. Mincle-MediatedImmunityto Mycobacteria
In addition to fungi, Mincle can recognise MTB, an activity
which requires the EPN motif within the carbohydrate
recognition domain of this receptor [63]. To identify the
speciﬁc ligand for this receptor in mycobacteria, Ishikawa
et al. analyzed various components of M. smegmatis lipid
extracts using chromatographic techniques. These screening
experiments revealed TDM as the mycobacterial ligand
for Mincle. TDM is made up of a trehalose moiety and
two mycolate chains [68], components which could not
individually activate Mincle-expressing cells, indicating that
a combination of both the sugar and the lipid moieties of
this glycolipid are important for its interaction with Mincle
[63]. Another independent report by Schoenen et al. has
conﬁrmed Mincle as the major receptor of TDM [69].
As discussed above, the mycobacterial cord factor TDM
anditssyntheticanalogueTDBcanactivatetheSyk-CARD9-
Bcl10 pathway and induce antimycobacterial immunity
[25]. Mincle was identiﬁed as the main receptor initiating
this signalling pathway and driving the TDM/TDB-induced
antimycobacterialimmunity[63,69].LossofMincleresulted
ingreatlyreducedproductionofinﬂammatorycytokinesand
nitric oxide in vitro [63, 69]. Further in vitro analysis also
demonstrated that the TDM/TDB-induced expression of G-
CSF and IL-1β in BMMø was abrogated in the FcRγ−/−
cells, conﬁrming the involvement of the FcRγ adaptor
chain in Mincle-mediated signalling [69]. In vivo, Mincle-
deﬁcient and FcRγ-deﬁcient mice had decreased TDM-
induced IL-6 and TNF production in the sera [69]. These
results indicate the critical roles of Mincle and FcRγ in
the innate immune responses induced by the mycobacterial
glycolipids.
To investigate the role of Mincle in driving TDB-
induced cellular immunity, Schoenen et al. analysed T cell
responses in the draining lymph nodes of wild-type and
Mincle-deﬁcientmicefollowingvaccinationwiththesubunit
vaccine H1 (an MTB fusion protein of Ag85B and ESAT-
6). Compared to the wild-type mice, which produced robust
amountsofIFN-γ andIL-17,thereweresigniﬁcantlyreduced
T cell numbers in the lymph nodes of Mincle-deﬁcient
mice when TDB was used as an adjuvant, indicating that
Mincle is responsible for the Th1 and Th17 responses
induced by this glycolipid [69]. The T cell responses were
also FcRγ dependent [69]. Thus, the Mincle-FcRγ signalling
pathway is crucial in the induction of Th1 and Th17
protective immunity that is triggered by the mycobacterial
glycolipids in this setting (see Figure 1). Collectively, these
data suggest that Mincle is a key receptor involved in the
induction of the CARD9 signalling pathway in response to
MTB.
8. SIGNR3inHost Response to
M. tuberculosis Infection
Other Syk-dependent receptors have been implicated in the
control of M. tuberculosis infection. Recently a study by
Tanne et al. reported that SIGNR3, a murine homologue
of DC-SIGN, that signals via intracellular hemITAM is
important for early immune response to M. tuberculosis
infection [70]. The authors demonstrated that SIGNR3 can
directly interact with live M. tuberculosis and promote the
ability of ﬁbroblasts to mediate endocytosis and to takeClinical and Developmental Immunology 7
up ManLAM [70]. To investigate the eﬀects of SIGNR3
deﬁciency on host resistance to mycobacterial infection,
the authors infected SIGNR3 knockout and wild-type mice
with M. tuberculosis and compared their ability to control
the infection. Although the SIGNR3-deﬁcient mice had
signiﬁcantly higher amounts of the lung bacilli, their ability
to mount Th1, Th2, Tc1, and Th17 responses was similar to
the wild-type mice. In addition, there were no diﬀerences
in the formation of granulomatous lesions and the survival
patterns between the SIGNR3-deﬁcient and the control mice
[70]. These results indicated that SIGNR3 is important in
early host resistance to M. tuberculosis but redundant for
the establishment of long-term defence against the infection
[70].
Tanne et al. also demonstrated that stimulation of the
SIGNR3-expressing macrophages with either ManLAM or
live M. tuberculosis resulted in the production of high
amounts of IL-6 and TNF in comparison with the control
cells [70]. Speciﬁc inhibition of Syk by piceatannol abolished
SIGNR3 signalling and the cytokine production in a dose
dependent manner, allowing the authors to conclude that
the SIGNR3-mediated production of IL-6 and TNF occurred
in a Syk-dependent manner [70]. Conclusively, the work by
Tanne et al. provided evidence that the Syk-coupled CLR
SIGNR3 plays a role in early host resistance to M. tuberculosis
in mice [70].
Because of the diﬀerences between SIGNR3 and the
relatedhumanmolecule,DC-SIGN,itisdiﬃculttospeculate
on the implication of the current murine SIGNR3 data in
thehumaninfections.DC-SIGNutilizesadiﬀerentsignalling
mechanism from the mouse homologue; it does not require
Syk kinase for signalling [71], but its interaction with
ManLAM leads to the activation of serine/threonine kinase
Raf-1 [72]. In vitro work has shown that DC-SIGN can
be exploited by M. tuberculosis to evade the host immune
surveillance [73]. Furthermore, a clinical study investigating
eﬀects of polymorphisms in the gene of DC-SIGN has
suggested that decreased level of DC-SIGN is associated with
increased protection against TB [74].
9. Concluding Remarks
Many PRRs that recognise mycobacteria have been identi-
ﬁed, but those studied to date appear to be largely redundant
when examined in vivo. The identiﬁcation of the Mincle
and the CARD9 pathway provides the ﬁrst evidence for
an essential nonredundant signalling that is crucial for
antimycobacterial immunity. However, more work is needed
to determine if Mincle promotes protective or nonprotective
responses during Mtb infection in vivo. Furthermore, given
the number of PRRs that can activate the Syk/CARD9
pathway it is likely that there are other receptors feeding
into this pathway. Special attention should be given to FcRγ-
associated PRRs, such as Dectin-2 which also recognise MTB
[75]. Identifying these receptors, and understanding their
roles during infection, will be critical if we wish to use this
information for the development of novel adjuvants and/or
vaccines.
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